A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies
The purpose of this study is to see what effects, good or bad, the experimental drug voruciclib has on patients with relapsed (cancer returned after previous treatment regimen) and/or refractory (cancer did not respond to previous treatment regimen) B cell malignancies such as follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), or acute myeloid leukemia (AML).
Relapsed and/or refractory follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), and acute myeloid leukemia (AML)
- Men and women at least 18 years of age who have FL, MCL, MZL, SLL, CLL, DLBCL, or AML
- You must have disease that has relapsed or is refractory to 2 or more prior treatment regimens and you are in need of treatment due to progressive disease
- You must have received all appropriate standard of care therapy for your disease and have developed disease progression or are intolerant to appropriate standard of care therapy
18 - 99
Healthy Volunteers Needed
Duration of Participation
You will get the study drug for as long as you are benefiting from treatment, or until your disease gets worse or the side effects become too severe.
Clinical Trials Information Line
MEI Pharma, Inc.